Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials | Nano Letters
Targeting natural killer cells to enhance vaccine responses: Trends in Pharmacological Sciences
Sequence-specific Labeling of Nucleic Acids and Proteins with Methyltransferases and Cofactor Analogues | Protocol (Translated to German)
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 | Scientific Reports
Optimization, Production, and Characterization of a CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced Immunogenicity of Anthrax Protective Antigen | Bioconjugate Chemistry
Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic - Wang - 2022 - Exploration - Wiley Online Library
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
Co-delivery of antigen and dual adjuvants by aluminum hydroxide nanoparticles for enhanced immune responses - ScienceDirect
CpG ODN (1826), TLR9 ligand (Class B) | Abeomics | Biomol.de
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
CpG ODN (1826), TLR9 ligand (Class B) | Abeomics | Biomol.de
Sequence List of CpG-C ODNs | Download Table
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice | npj Vaccines
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
CpG oligodeoxynucleotide - Wikipedia
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 | Scientific Reports
Frontiers | CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance
Development of the CpG Adjuvant 1018: A Case Study | SpringerLink
Vaccines | Free Full-Text | CpG 1018 Is an Effective Adjuvant for Influenza Nucleoprotein
Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses | PLOS ONE
Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60–70 years - ScienceDirect
Frontiers | Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21
